Cipla Results

Cipla's stock was up 3 per cent during the day's trade on the BSE in the afternoon

The company's consolidated net profit increased nearly 49 per cent to Rs 1,571 crore ($181.6 million) in the October-December quarter,

At 6:31 AM, GIFT Nifty futures pointed to a positive start, trading 76 points higher at 22,922

The uptick in Cipla share price came after the United States Food and Drug Administration (USFDA) on Wednesday classified Goa facility as Voluntary Action Indicated (VAI)

Drug major Cipla on Tuesday reported a 17 per cent increase in consolidated net profit to Rs 1,303 crore for the second quarter ended September 2024, driven by robust sales across markets. The company had reported a net profit of Rs 1,115 crore in the July-September quarter of the last fiscal. Its total income from operations rose to Rs 7,051 crore in the second quarter compared to Rs 6,490 crore in the year-ago period, Cipla said in a regulatory filing. "In Q2 FY25, we recorded a revenue growth of 9 per cent over the last year with a highest-ever EBITDA margin of 26.7 per cent driven by mix and other operational efficiencies," Cipla MD and Global CEO Umang Vohra said. The company's 'One-India' business was impacted during the quarter due to a changed seasonal pattern. However key chronic therapies in the branded prescription business continued to grow faster than the market, he added. The company's consumer health business grew at a strong 21 per cent year-on-year, Vohra said. "

Shares of Cipla dropped 3.55 per cent at Rs 1,450 per share on the BSE in Tuesday's intraday trade

Analysts expect Cipla to register a low single digit rise in the topline and bottomline, with margins being impacted by modest sales in the US and domestic formulations

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

Cipla was in a downtrend and corrected ~13 per cent in the recent fall. On the daily charts it formed an Inverted Head and Shoulders pattern which is a Trend reversal pattern

At 6:55 AM, GIFT Nifty futures was trading 73 points higher at 22,382.50 levels compared to Nifty50 futures, indicating a positive start for the bourses

The management has guided 24.5 per cent-25.5 per cent Ebitda margin for FY25

Eyes further market expansion and partnerships in FY25

Cipla Q4FY24 results: The company board has recommended a final dividend of Rs 13 per equity share, to be paid within 30 days from the date of the annual general meeting (AGM)

Cipla may show a 3-10 per cent jump in its topline year-on-year (Y-o-Y), registering revenues in the range of Rs 5,939 crore and Rs 6,292 crore

Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug

The company reported a 13.7 per cent increase in sales to Rs 6,603 crore led by 11.5 per cent growth in the India business

Cipla advanced its board meeting to January 22 to approve its results for the quarter and nine months ended December 31, 2023, to avoid confusion following an alleged social media leak

The collaborative effort is aimed at developing and commercialising novel Cell therapy products for critical unmet medical needs in the US, Japan, and the EU

Closing Bell on November 7, 2023: The broader markets, on the other hand, held steady gains throughout the session, settling 0.53 per cent and 0.38 per cent higher, respectively